29
May
2023
Category: Blog
15
May
2023
Bionest
GLP-1 Agonists: The Next Pharma El Dorado? – Part 1
Will GLP-1RAs ultimately succeed in the marketplace for obesity treatments, where other weight loss drugs have failed? In the first of a two-part blog series, we explore their use as a treatment of Type 2 diabetes & obesity.
1
May
2023
Bionest
Reactions to the Inflation Reduction Act and Drug Pricing
What impact will the Inflation Reduction Act have on pharmaceutical businesses, innovation and patients?
17
Apr
2023
Bionest
Evolving Gene Therapy Vectors for Greater Utility and Safety
Gene therapy has come a long way since it first emerged in the 1990s. Could new gene delivery strategies enable even wider applications?
3
Apr
2023
Bionest
The Growth of the Metaverse into Life Sciences and Health Care
Augmented reality, VR & other aspects of the metaverse are beginning to impact healthcare, from disability & elder care to hospital triage, surgical training, clinical trial monitoring, mental health & physical therapy.
20
Mar
2023
Bionest
FDA Finalizes Guidance on Multiple Endpoints in Clinical Trials
Assessing multiple endpoints in clinical trial results can prove challenging, prompting the FDA to provide new guidance for drug sponsors.
13
Mar
2023
Bionest
Alzheimer’s Disease Update Part 2: The Importance of Amyloid and Its Clearance in AD
Could cellular waste management be key in treating Alzheimer's Disease? We explore this emerging field of research and potential for new AD drugs.
21
Feb
2023
Bionest
Alzheimer’s Disease Update Part 1: Lecanemab Provides New Support for the Amyloid Hypothesis
What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
6
Feb
2023
Bionest
Innovation in Generics: New Oral Drug Delivery System for IBD and Beyond
Novel drug delivery systems offer a valuable approach to differentiating drugs, especially those competing within a generic market
23
Jan
2023